Zenas Biopharma, Common Etf Market Value
| ZBIO Etf | USD 10.44 2.01 16.14% |
| Symbol | Zenas |
The market value of Zenas BioPharma, Common is measured differently than its book value, which is the value of Zenas that is recorded on the company's balance sheet. Investors also form their own opinion of Zenas BioPharma,'s value that differs from its market value or its book value, called intrinsic value, which is Zenas BioPharma,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zenas BioPharma,'s market value can be influenced by many factors that don't directly affect Zenas BioPharma,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zenas BioPharma,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Zenas BioPharma, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zenas BioPharma,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Zenas BioPharma, 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Zenas BioPharma,'s etf what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Zenas BioPharma,.
| 10/23/2024 |
| 11/22/2024 |
If you would invest 0.00 in Zenas BioPharma, on October 23, 2024 and sell it all today you would earn a total of 0.00 from holding Zenas BioPharma, Common or generate 0.0% return on investment in Zenas BioPharma, over 30 days. Zenas BioPharma, is related to or competes with EnGene Holdings, GRI Bio, Prime Medicine,, Amylyx Pharmaceuticals, FT Vest, and Zillow Group. The investment seeks daily investment results, before fees and expenses, that correspond to three times the inverse of t... More
Zenas BioPharma, Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Zenas BioPharma,'s etf current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Zenas BioPharma, Common upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.18) | |||
| Maximum Drawdown | 26.69 | |||
| Value At Risk | (12.78) | |||
| Potential Upside | 8.86 |
Zenas BioPharma, Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Zenas BioPharma,'s investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Zenas BioPharma,'s standard deviation. In reality, there are many statistical measures that can use Zenas BioPharma, historical prices to predict the future Zenas BioPharma,'s volatility.| Risk Adjusted Performance | (0.11) | |||
| Jensen Alpha | (1.12) | |||
| Total Risk Alpha | (1.67) | |||
| Treynor Ratio | (0.46) |
Zenas BioPharma, Common Backtested Returns
Zenas BioPharma, Common shows Sharpe Ratio of -0.16, which attests that the etf had a -0.16% return per unit of risk over the last 3 months. Zenas BioPharma, Common exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Zenas BioPharma,'s Market Risk Adjusted Performance of (0.45), mean deviation of 4.11, and Standard Deviation of 5.75 to validate the risk estimate we provide. The entity maintains a market beta of 1.98, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Zenas BioPharma, will likely underperform.
Auto-correlation | 0.45 |
Average predictability
Zenas BioPharma, Common has average predictability. Overlapping area represents the amount of predictability between Zenas BioPharma, time series from 23rd of October 2024 to 7th of November 2024 and 7th of November 2024 to 22nd of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Zenas BioPharma, Common price movement. The serial correlation of 0.45 indicates that just about 45.0% of current Zenas BioPharma, price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.45 | |
| Spearman Rank Test | 0.3 | |
| Residual Average | 0.0 | |
| Price Variance | 15.52 |
Zenas BioPharma, Common lagged returns against current returns
Autocorrelation, which is Zenas BioPharma, etf's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Zenas BioPharma,'s etf expected returns. We can calculate the autocorrelation of Zenas BioPharma, returns to help us make a trade decision. For example, suppose you find that Zenas BioPharma, has exhibited high autocorrelation historically, and you observe that the etf is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Zenas BioPharma, regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Zenas BioPharma, etf is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Zenas BioPharma, etf is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Zenas BioPharma, etf over time.
Current vs Lagged Prices |
| Timeline |
Zenas BioPharma, Lagged Returns
When evaluating Zenas BioPharma,'s market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Zenas BioPharma, etf have on its future price. Zenas BioPharma, autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Zenas BioPharma, autocorrelation shows the relationship between Zenas BioPharma, etf current value and its past values and can show if there is a momentum factor associated with investing in Zenas BioPharma, Common.
Regressed Prices |
| Timeline |
Pair Trading with Zenas BioPharma,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Zenas BioPharma, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Zenas BioPharma, will appreciate offsetting losses from the drop in the long position's value.Moving against Zenas Etf
| 0.5 | VINC | Vincerx Pharma | PairCorr |
| 0.36 | VCEL | Vericel Corp Ord | PairCorr |
| 0.33 | DTIL | Precision BioSciences | PairCorr |
The ability to find closely correlated positions to Zenas BioPharma, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Zenas BioPharma, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Zenas BioPharma, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Zenas BioPharma, Common to buy it.
The correlation of Zenas BioPharma, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Zenas BioPharma, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Zenas BioPharma, Common moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Zenas BioPharma, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Zenas Etf
Zenas BioPharma, financial ratios help investors to determine whether Zenas Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zenas with respect to the benefits of owning Zenas BioPharma, security.